Definitive Healthcare price target raised to $15 from $13 at Canaccord

Canaccord analyst David Hynes raised the firm’s price target on Definitive Healthcare to $15 from $13 and keeps a Buy rating on the shares. The analyst met with management and said the tone was generally upbeat as investors clearly see value here given near-category leading cash margins, but are wrestling with whether mid-teens growth next year is sufficiently de-risked.